Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 4/2015

01-04-2015 | New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)

Post Partial Nephrectomy Surveillance Imaging: an Evidence-Based Approach

Authors: Lorenzo Marconi, Michael A. Gorin, Mohamad E. Allaf

Published in: Current Urology Reports | Issue 4/2015

Login to get access

Abstract

To ensure the early detection of recurrent disease, all patients should undergo routine surveillance following partial nephrectomy for renal cell carcinoma. In order to optimize resource allocation and avoid unnecessary radiation exposure, the frequency and duration of surveillance should be tailored to the individual patient’s risk of cancer recurrence. The evidence for surveillance after partial nephrectomy is presented reviewing the current literature on prognostic models and proposed surveillance protocols based on the timing and patterns of renal cell carcinoma recurrence. In addition, we review recent guidelines on post partial nephrectomy surveillance as well as the literature on novel imaging techniques that may aid in early disease discovery.
Literature
1.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin. 2014;64:9–29.
2.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int du Cancer. 2010;127:2893–917.CrossRef
3.
Gill IS, Aron M, Gervais DA, Jewett MA. Clinical practice. Small renal mass. N Engl J Med. 2010;362:624–34.CrossRefPubMed
4.
Miller DC, Saigal CS, Banerjee M, Hanley J, Litwin MS. Urologic Diseases in America P. Diffusion of surgical innovation among patients with kidney cancer. Cancer. 2008;112:1708–17.CrossRefPubMedCentralPubMed
5.
Woldrich JM, Palazzi K, Stroup SP, Sur RL, Parsons JK, Chang D, et al. Trends in the surgical management of localized renal masses: thermal ablation, partial and radical nephrectomy in the USA, 1998–2008. BJU Int. 2013;111:1261–8.CrossRefPubMed
6.
Poon SA, Silberstein JL, Chen LY, Ehdaie B, Kim PH, Russo P. Trends in partial and radical nephrectomy: an analysis of case logs from certifying urologists. J Urol. 2013;190:464–9.CrossRefPubMedCentralPubMed
7.
Weight CJ, Larson BT, Fergany AF, Gao T, Lane BR, Campbell SC, et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol. 2010;183:1317–23.CrossRefPubMed
8.
Kim SP, Thompson RH, Boorjian SA, Weight CJ, Han LC, Murad MH, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol. 2012;188:51–7.CrossRefPubMed
9.
Mariusdottir E, Jonsson E, Marteinsson VT, Sigurdsson MI, Gudbjartsson T. Kidney function following partial or radical nephrectomy for renal cell carcinoma: a population-based study. Scand J Urol. 2013;47:476–82.CrossRefPubMed
10.
Yap SA, Finelli A, Urbach DR, Tomlinson GA, Alibhai SM. Partial Nephrectomy for the Treatment of Renal Cell Carcinoma and the Risk of End Stage Renal Disease. BJU Int. 2014.
11.
Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271–9.CrossRefPubMed
12.••
13.••
Ljungberg BBK, Bex A, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk M, Lam T, Marconi L, Merseburger L, Mulders P, Powles T, Staehler M, Volpe A, Renal Cell Cancer Guidelines. 2014. The 2014 guideline from the EAU proposes an algorithm for surveillance based risk-stratification using one of the validated classification systems.
14.
Dabestani S, Marconi L, Hofmann FSF, Lam T, Canfield S, Staehler M, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014;15:e549–61.CrossRefPubMed
15.
Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer. 2014;110:2821–8.CrossRefPubMedCentralPubMed
16.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27:3584–90.CrossRef
17.
Lipsky MJ, Shapiro EY, Hruby GW, McKiernan JM. Diagnostic radiation exposure during surveillance in patients with pT1a renal cell carcinoma. Urology. 2013;81:1190–5.CrossRefPubMed
18.
Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63–7.CrossRefPubMed
19.
Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173:48–51.CrossRefPubMed
20.
Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663–71.CrossRefPubMed
21.
Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Leibovich BC, et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol. 2003;170:2225–32.CrossRefPubMed
22.
Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2002;20:4559–66.CrossRef
23.
Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005;174:466–72. discussion 72; quiz 801.CrossRefPubMed
24.
Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol. 2011;60:644–61.CrossRefPubMed
25.
Heidenreich A, Schrader AJ, Varga Z. Basic science and research in renal cell carcinoma: from workbench to bedside. Curr Opin Urol. 2003;13:457–62.CrossRefPubMed
26.
Small AC, Gong Y, Oh WK, Hall SJ, van Rijn CJ, Galsky MD. The emerging role of circulating tumor cell detection in genitourinary cancer. J Urol. 2012;188:21–6.CrossRefPubMed
27.
Antonelli A, Cozzoli A, Zani D, Zanotelli T, Nicolai M, Cunico SC, et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int. 2007;99:296–300.CrossRefPubMed
28.
Hafez KS, Novick AC, Campbell SC. Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol. 1997;157:2067–70.CrossRefPubMed
29.
Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159:1163–7.CrossRefPubMed
30.
Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 1999;84:405–11.CrossRefPubMed
31.
Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol. 1995;154:28–31.CrossRefPubMed
32.
Siddiqui SA, Frank I, Cheville JC, Lohse CM, Leibovich BC, Blute ML. Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol. BJU Int. 2009;104:778–85.CrossRefPubMed
33.
Stephenson AJ, Chetner MP, Rourke K, Gleave ME, Signaevsky M, Palmer B, et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol. 2004;172:58–62.CrossRefPubMed
34.
Brookman-May S, May M, Shariat SF, Xylinas E, Stief C, Zigeuner R, et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol. 2013;64:472–7.CrossRefPubMed
35.
Adamy A, Chong KT, Chade D, Costaras J, Russo G, Kaag MG, et al. Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol. 2011;185:433–8.CrossRefPubMed
36.
Khalifeh A, Kaouk JH, Bhayani S, Rogers C, Stifelman M, Tanagho YS, et al. Positive surgical margins in robot-assisted partial nephrectomy: a multi-institutional analysis of oncologic outcomes (leave no tumor behind). J Urol. 2013;190:1674–9.CrossRefPubMed
37.••
Donat SM, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, Herrell SD III, Hilton S, Jonasch E, Lin DW, Reuter VE, Chang SS. Follow-up for clinically localized renal neoplasms: AUA guideline. 2013. The AUA guidelines on the surveillance of patients with clinically-localized RCC after treatment with surgery or ablative procedures. The recommendations are based on a well conducted systematic review of the literature.
38.
Stewart F, Thompson H, Psutka S, Cheville J, Lohse C, Boorjian S, Leibovich B. Evaluation of the National Comprehensive Cancer Network and American Urological Association Renal Cell Carcinoma Surveillance Guidelines. J Clin Oncol. 2014. in press.
39.
Wang HY, Ding HJ, Chen JH, Chao CH, Lu YY, Lin WY, et al. Meta-analysis of the diagnostic performance of [18 F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging : Off Publ Int Cancer Imaging Soc. 2012;12:464–74.CrossRef
40.
Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2003;21:3995–4000.CrossRef
41.
Kumar R, Shandal V, Shamim SA, Jeph S, Singh H, Malhotra A. Role of FDG PET-CT in recurrent renal cell carcinoma. Nucl Med Commun. 2010;31:844–50.PubMed
42.
Nakatani K, Nakamoto Y, Saga T, Higashi T, Togashi K. The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol. 2011;79:29–35.CrossRefPubMed
43.•
Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31:187–94. A prospective fully-paired direct comparison of girentuximab PET/CT to multiphasic contrast-enhanced CT to characterize renal masses.CrossRef
44.
Povoski SP, Hall NC, Murrey Jr DA, Sharp DS, Hitchcock CL, Mojzisik CM, et al. Multimodal imaging and detection strategy with 124 I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma. Surg Innov. 2013;20:59–69.CrossRefPubMedCentralPubMed
45.
Stillebroer AB, Boerman OC, Desar IM, Boers-Sonderen MJ, van Herpen CM, Langenhuijsen JF, et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2013;64:478–85.CrossRefPubMed
46.
Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496–507.CrossRefPubMed
Metadata
Title
Post Partial Nephrectomy Surveillance Imaging: an Evidence-Based Approach
Authors
Lorenzo Marconi
Michael A. Gorin
Mohamad E. Allaf
Publication date
01-04-2015
Publisher
Springer US
Published in
Current Urology Reports / Issue 4/2015
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-015-0489-7

Other articles of this Issue 4/2015

Current Urology Reports 4/2015 Go to the issue

Men’s Health (R Carrion and C Yang, Section Editors)

Strategies for Penile Prosthesis Placement in Peyronie’s Disease and Corporal Fibrosis

New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)

Preoperative Imaging for Staging Bladder Cancer

New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)

Contemporary Assessment of Renal Stone Complexity Using Cross-Sectional Imaging

New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)

Near-Infrared Fluorescence Imaging with Intraoperative Administration of Indocyanine Green for Robotic Partial Nephrectomy

Urothelial Cancer (A Sagalowsky, Section Editor)

Preoperative and Modifiable Factors to Lower Postoperative Complications After Radical Cystectomy

Prostate Cancer (A Kibel, Section Editor)

Active Surveillance for Low-Risk Prostate Cancer